Rocket Pharmaceuticals Inc (RCKT) 13F Holders & Ownership Data (180 Funds, Q2 2026)

RCKT ranks #3266 out of 37501 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

180 institutions disclose a position in RCKT, but none treat it as a major bet — even Newtyn Management, LLC, its most concentrated holder, allocates just 1.7% of its own portfolio to it.

Marshall Wace, LLP has added to its RCKT position for two straight quarters, increasing it by $13.7M to reach $13.8M today.

Morgan Stanley has trimmed its RCKT position for two straight quarters, cutting it by $10.2M while still holding $3.6M.

RCKT is up 6.6% today, and institutions have been net buyers of $17.1M this quarter — today's price move and the underlying institutional flow are pointing the same direction.

RCKT reported a net loss of $17.3M over the trailing twelve months.

• Not yet profitable — net loss of $17.3M over the trailing twelve months
• Net income improved year over year, from -$257.3M to -$17.3M
• Operating cash flow was negative, using $190.0M in cash
• Current ratio of 6.38x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.19x equity — within a conventional range